Bioequivalence and Pharmacokinetic Evaluation of Regorafenib Tablets in Healthy Chinese Volunteers
Clinical Pharmacology in Drug Development · 2024
DOI: 10.1002/cpdd.1474 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Zhaoyu Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacokinetics Laboratory, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Food-Drug Interactions, Phenylurea Compounds, Pyridines, Therapeutic Equivalency. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
This was a single‐center, randomized, open‐label, 2‐formulation, and 2‐cycle crossover trial conducted in 48 healthy Chinese volunteers, under fasting and fed conditions. The participants received oral doses of the test formulation (regorafenib) and reference formulation (40 mg) during each study period. Blood samples were collected before and up to 144 hours after the formulations were administered to determine changes in the pharmacokinetic parameters and adverse reactions, which were then used to evaluate bioequivalence and safety. The geometric mean ratios of maximum blood concentration, area under the plasma concentration‐time curve from time 0 to the last quantifiable concentration , and area under the plasma concentration‐time curve from time 0 to infinity for regorafenib were as follows: 94.7%, 91.4%, and 91.7%, respectively, under fasting conditions; and 94.6%, 97.7%, and 98.8%, respectively, under fed conditions. The 90% confidence intervals for the geometric mean ratios were within the 80%‐125% equivalence interval for both the fasting and fed tests. Ingesting high‐fat and high‐calorie foods increases exposure to regorafenib, leading to slower rates of absorption. The safety profiles of the 2 preparations were similar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacokinetics Laboratory, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Zitieren
APA
Wang, Z., Zhang, Y., Liu, J., & Chen, X. (2024). Bioequivalence and Pharmacokinetic Evaluation of Regorafenib Tablets in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1474
Vancouver
Wang Z, Zhang Y, Liu J, Chen X. Bioequivalence and Pharmacokinetic Evaluation of Regorafenib Tablets in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1474
BibTeX
@article{Wang2024,
author = {Wang, Zhaoyu and Zhang, Yun and Liu, Jingjing and Chen, Xijing},
title = {Bioequivalence and Pharmacokinetic Evaluation of Regorafenib Tablets in Healthy Chinese Volunteers},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
doi = {10.1002/cpdd.1474}
}
EUVIMED